Company intelligence / Profile preview
Sichuan Kelun-Biotech Biopharmaceutical
Chengdu, Sichuan, Chinaen.kelun-biotech.com ↗
- Ownership
- Public · 06990.HK
- Development stage
- Other
01
Overview
Kelun-Biotech has over a decade of experience in ADC development with an integrated R&D platform. Its lead asset sacituzumab tirumotecan ("sac-TMT"), a TROP2-targeting ADC, received marketing authorization in China for two indications as of early 2025—triple-negative breast cancer and EGFR mutant-positive non-squamous NSCLC post-EGFR-TKI/platinum therapy. The company has more than ten clinical-stage assets across oncology and other therapeutic areas.
- Therapeutic areas
- OncologyDermatologyNephrology
- Modalities
- Antibody-drug conjugateMonoclonal antibodyBispecific monoclonal antibodySmall molecule
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Merck Sharp & Dohme/MSD – up to nine ADC assets licensed globally with potential deal value up to $11.8 billion USD.
04
Financials
- Market cap
- $13.9B
- Total revenue
- $308.5M
- Enterprise value
- $13.2B
Beyond the preview
Go deeper on Sichuan Kelun-Biotech Biopharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sichuan Kelun-Biotech Biopharmaceutical.